4-methyl-3-(phenylsulfonyl)furoxan has been researched along with 1-methyl-3-isobutylxanthine in 1 studies
Studies (4-methyl-3-(phenylsulfonyl)furoxan) | Trials (4-methyl-3-(phenylsulfonyl)furoxan) | Recent Studies (post-2010) (4-methyl-3-(phenylsulfonyl)furoxan) | Studies (1-methyl-3-isobutylxanthine) | Trials (1-methyl-3-isobutylxanthine) | Recent Studies (post-2010) (1-methyl-3-isobutylxanthine) |
---|---|---|---|---|---|
5 | 0 | 0 | 5,148 | 5 | 279 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alessio, P; Bussolino, F; Calvino, R; Fruttero, R; Gasco, A; Ghigo, D; Heller, R; Pescarmona, G; Till, U; Todde, R | 1 |
1 other study(ies) available for 4-methyl-3-(phenylsulfonyl)furoxan and 1-methyl-3-isobutylxanthine
Article | Year |
---|---|
S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells.
Topics: 1-Methyl-3-isobutylxanthine; Acetyltransferases; Cells, Cultured; Colforsin; Cyclic AMP; Cyclic GMP; Endothelium, Vascular; Enzyme Activation; Epoprostenol; Humans; Iloprost; Oxadiazoles; Platelet Activating Factor; Platelet Aggregation Inhibitors; Thrombin; Umbilical Veins | 1993 |